A Phase 3 interventional study of alpha-1 proteinase inhibitor (human) in Alpha 1-Antitrypsin Deficiency, sponsored by Grifols Therapeutics LLC. Completed at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-19.
Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency — 2 open to participants now, 2 under way, 1 of them phase 3. alpha 1-Antitrypsin · alpha 1-Antitrypsin Deficiency.
Among the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency, this one is the 9th largest by enrollment, is one of 4 that started in 2006, is one of 7 in phase 3, and was the 4th registered.
142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.
Browse alpha 1-Antitrypsin Deficiency studies →2 of the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency are open now, in 12 countries. Recruiting first, the newest first:
CSL Behring · Sites in Denmark
Ages 18–65
Grifols Therapeutics LLC · Sites in United States, Australia, Canada and 9 more countries
Ages 20–72
By country, each count listing its studies:
alpha 1-Antitrypsin: first FDA approval 1987 (prolastin,prolastin-c,prolastin-c liquid), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10 · Phase 3 7 · Phase 4 6
First in 2003; this study’s year is marked. 4 started in 2006.
This study's enrollment of 38 is above the median of 33 across 86 interventional studies indexed under alpha 1-Antitrypsin Deficiency.
Median enrollment 30 across the 25 interventional studies. Of the 19 that completed or were terminated, 16 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 25 have an industry lead sponsor. The 10 most frequent:
This study is registered under Grifols Therapeutics LLC, one of the names counted as Grifols. Under that name alone:
Grifols Therapeutics LLC is the lead sponsor of 46 studies on the registry; 4 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.
12 studies in alpha 1-Antitrypsin Deficiency by Grifols: 2 open now, 2 under way, 2 of them phase 3. Of 10 finished, 9 (90%) have results posted.
Among the 12 studies in alpha 1-Antitrypsin Deficiency by Grifols, this one is the 6th largest by enrollment, is one of 2 that started in 2006, is one of 5 in phase 3, and was the 3rd registered.
Grifols’s alpha 1-Antitrypsin Deficiency studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency, from their registry updates:
Among Grifols’s 12 in alpha 1-Antitrypsin Deficiency:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical study is to assess the safety and tolerability of Alpha-1 MP in adult Alpha1-antitrypsin deficient patients.
The objective of this clinical trial (STAMP: Safety and Tolerability of Alpha-1 Modified Process) is to study the safety and tolerability of Alpha-1 MP in adult Alpha 1-antitrypsin deficient subjects as reported over 20 weeks of therapy. The primary objective is to describe the nature and frequency of treatment-emergent adverse events with "treatment-emergent" defined as any adverse event occurring after the start of the first study drug infusion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study the safety and tolerability of weekly infusions of Alpha-1 Proteinase Inhibitor (Human), modified process (Alpha-1 MP, 60 mg/kg) over 20 weeks of therapy in adult Alpha-1 antitrypsin deficient subjects.
Drug: alpha-1 proteinase inhibitor (human)
60 mg/kg weekly for 20 weeks
Also known as: Prolastin, Alpha-1 antitrypsin (AAT), BAY x 5747, BAY 10-5233, TAL-05-00007
Treatment-emergent Adverse Events (TEAEs) Defined as Any Adverse Event (AE) Occurring During or After the Start of the First Study Drug Infusion.
An adverse event is any untoward medical occurrence in a subject or clinical investigation subject administered with a pharmaceutical product. The adverse event does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the medicinal product.
Time frame: 24 weeks
First-subject-first-dose was 12 June 2006, last-subject-last-visit was 20 March 2007. The study was performed in 10 clinical sites, 8 sites in the United States and 2 sites in the United Kingdom.
| Milestone | Alpha-1MP Treatment Group |
|---|---|
| Started | 38 |
| Completed | 37 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
An adverse event is any untoward medical occurrence in a subject or clinical investigation subject administered with a pharmaceutical product. The adverse event does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the medicinal product.
| Participants | Alpha-1 MP Treatment Group |
|---|---|
| Number of Participants Analyzed | 38 |
| Subjects experiencing TEAEs | 26 |
| Subjects with TEAEs <24 hrs. of A-1 MP infusion | 17 |
| Alpha-1 MP subjects with ≥1 drug-related TEAE | 5 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alpha-1MP Treatment Group | — | 2/38 (5.3%) | 26/38 (68.4%) |
| Event | Alpha-1MP Treatment Group |
|---|---|
| PneumoniaInfections and infestations | 1/38 |
| RashSkin and subcutaneous tissue disorders | 1/38 |
| Event | Alpha-1MP Treatment Group |
|---|---|
| NauseaGastrointestinal disorders | 6/38 |
| Upper respiratory tract infectionInfections and infestations | 6/38 |
| Urinary tract infectionInfections and infestations | 5/38 |
| Chest painGeneral disorders | 4/38 |
| Influenza like illnessGeneral disorders | 2/38 |
| ChillsGeneral disorders | 2/38 |
| NasopharyngitisInfections and infestations | 2/38 |
| Oral candidiasisInfections and infestations | 2/38 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/38 |
| Back painMusculoskeletal and connective tissue disorders | 2/38 |
| Age, Categorical(Participants) | Entered Study |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 32 |
| >=65 years | 6 |
| Age, Continuous(years) | Entered Study |
|---|---|
| Mean | 53.4 ± 8.63 |
| Sex: Female, Male(Participants) | Entered Study |
|---|---|
| Female | 15 |
| Male | 23 |
| Region of Enrollment(participants) | Entered Study |
|---|---|
| United States | 35 |
| United Kingdom | 3 |
The record gives a start of Jun 2006, a primary completion of Mar 2007 and a completion of Mar 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 7 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alpha 1-Antitrypsin
alpha 1-Antitrypsin Deficiency →